The total return over the past 12 months is -83.01% vs. +19.88% for the S&P 500. So far it's up -72.60% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (83.01%) | (67.93%) | (57.05%) | (49.05%) | N/A | N/A |
| Total Return CAGR | (83.01%) | (67.93%) | (57.05%) | (49.05%) | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
PDS Biotechnology Corporation (PDSB)
| Year | Start price | End price | PDSB Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $0.77 | $0.21 | (72.60%) | +13.42% | (86.02%) |
| 2025 | $1.63 | $0.77 | (52.77%) | +17.72% | (70.49%) |
| 2024 | $4.97 | $1.63 | (67.20%) | +24.89% | (92.09%) |
| 2023 | $13.20 | $4.97 | (62.35%) | +26.19% | (88.54%) |
| 2022 | $8.10 | $13.20 | +62.96% | (18.17%) | +81.13% |
| 2021 | $2.14 | $8.10 | +278.50% | +28.74% | +249.76% |
| 2020 | $2.65 | $2.14 | (19.25%) | +18.37% | (37.62%) |
| 2019 | $6.42 | $2.65 | (58.72%) | +31.22% | (89.94%) |
| 2018 | $187.40 | $6.42 | (96.57%) | (4.56%) | (92.01%) |
| 2017 | $250.00 | $187.40 | (25.04%) | +21.70% | (46.74%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
